MEDS on Nasdaq
DataMeds AI, Inc.
American wholesale-drugs company, incorporated in Delaware. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Cellyan Biotechnology Co., Ltd, Cosmos Health Inc. or Stemtech Corp, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue100¢$29.8M
Out of $23.3M in revenue.3 The company lost money this year.
Financial statements
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $18.1M3 | $23.3M3 | ||
| Cost of revenue | $16.4M3 | $29.8M3 | ||
| Gross profit | $1.8M3 | -$6.4M3 | ||
| Operating expenses | $2.9M4 | $7.9M3 | $87.3M3 | |
| Operating income | -$2.9M4 | -$6.1M3 | -$93.7M3 | |
| Income before tax | -$2.9M4 | -$6.9M3 | -$101.3M3 | |
| Net income | -$2.9M4 | -$6.9M3 | -$101.3M3 | |
| Earnings per share | -$0.064 | -$0.153 | -$1.433 | |
| Earnings per share (diluted) | -$0.064 | -$0.153 | -$1.433 | |
| Shares (weighted, basic) | 44.7M shares4 | 47.3M shares3 | 71.0M shares3 | |
| Shares (weighted, diluted) | 44.7M shares4 | 47.3M shares3 | 71.0M shares3 |
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash | $1.4K4 | $1.0M3 | $42.6K3 | |
| Inventory | $9.5M3 | $1.6M3 | ||
| Current assets | $338.4K4 | $15.2M3 | $2.8M3 | |
| Property, plant and equipment | $388.2K3 | $229.4K3 | ||
| Goodwill | $16.2M3 | $14.2M3 | ||
| Intangible assets | $1.6M3 | $2.5M3 | ||
| Total assets | $338.4K4 | $57.3M3 | $30.5M3 | |
| Short-term debt | $350.0K4 | $11.5M4 | $10.9M3 | |
| Current liabilities | $2.9M4 | $38.0M3 | $29.8M3 | |
| Long-term debt | $11.5M3 | $12.6M3 | ||
| Total liabilities | $3.2M4 | $50.6M3 | $42.9M3 | |
| Retained earnings | -$2.9M4 | -$9.8M3 | -$111.0M3 | |
| Shareholders’ equity | -$5.2K4 | -$2.9M3 | $6.7M3 | -$12.4M3 |
| Shares outstanding | 44.7M shares4 | 51.1M shares3 | 101.3M shares3 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Leadership
Who has led DataMeds AI, Inc., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerBrian Norton Mar 12, 2025 to now7
- Chief financial officerMark Disiena Apr 23, 2025 to now8
Board members and other officers (14)
- Chief Clinical OfficerShafaat Pirani Feb 28, 2025 to now9
- Chief Pharmacy OfficerNikul Panchal Mar 14, 2025 to now10
- Chief Information OfficerSrinivas Kalla Apr 24, 2025 to now11
- Board memberMarlene Velez Apr 2, 2026 to now12
- Board memberEric Michael Sherb Apr 9, 2026 to now13
- Board memberGary L. Herman Apr 10, 2026 to now14
- Board memberDonald William Anderson Feb 24, 2025 to now15
- Board memberSurendra K. Ajjarapu Feb 24, 2025 to now16
- Board memberRebecca M. Shanahan Feb 28, 2025 to now17
- Board memberSajid Syed Feb 28, 2025 to now18
- Board memberMichael L. Peterson Jul 8, 2025 to now19
- Board memberSteven Dale Lee Oct 14, 2025 to now20
- Board memberDonald G. Fell Oct 21, 2025 to now21
- Board memberHoward A. Doss Oct 24, 2025 to now22
Former names
Timeline
- Mar 12, 2025New chief executive Brian Norton becomes CEO7
Filings
172 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 61 major events, 32 insider forms, 71 other. The latest 20:
- Oct 13, 20268-K EDGAR
- Oct 9, 2026PRE 14C EDGAR
- Oct 9, 2026S-1/A EDGAR
- Sep 17, 20268-K EDGAR
- Sep 16, 20268-K EDGAR
- Aug 31, 2026PRE 14C EDGAR
- Aug 18, 20268-K EDGAR
- Aug 17, 202610-Q EDGAR
- Aug 14, 20268-K EDGAR
- Aug 14, 2026NT 10-Q EDGAR
- Aug 7, 2026S-1 EDGAR
- Aug 4, 20268-K EDGAR
- Jul 29, 20268-K EDGAR
- Jul 21, 20268-K EDGAR
- Jun 25, 20264 EDGAR
- Jun 25, 20264 EDGAR
- Jun 25, 20264/A EDGAR
- Jun 25, 20264/A EDGAR
- Jun 18, 2026PRE 14A EDGAR
- Jun 12, 20268-K EDGAR
The 172 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Jane Street Group, LLC | 20,532 | $63.6K | 0.0% | New |
| Geode Capital Management, LLC | 12,467 | $38.6K | 0.0% | New |
| Vanguard Capital Management LLC | 11,085 | $34.4K | 0.0% | New |
| Vanguard Fiduciary Trust Co | 6,191 | $19.2K | 0.0% | New |
| Barclays PLC | 723 | $2.2K | 0.0% | New |
| Tower Research Capital LLC (TRC) | 678 | $2.1K | 0.0% | New |
| Fortitude Family Office, LLC | 118 | $366 | 0.0% | New |
| Integrated Wealth Concepts LLC | 25 | $78 | 0.0% | New |
| Global Retirement Partners, LLC | 2 | $6 | 0.0% | New |
| Danske Bank A/s | 1 | $3 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARMarlene Velez, Board member
- 13SEC EDGAREric Michael Sherb, Board member
- 14SEC EDGARGary L. Herman, Board member
- 15
- 16SEC EDGARSurendra K. Ajjarapu, Board member
- 17SEC EDGARRebecca M. Shanahan, Board member
- 18SEC EDGARSajid Syed, Board member
- 19SEC EDGARMichael L. Peterson, Board member
- 20SEC EDGARSteven Dale Lee, Board member
- 21SEC EDGARDonald G. Fell, Board member
- 22SEC EDGARHoward A. Doss, Board member